Intravenous Stem Cell Therapy for High-Grade Aneurysmal Subarachnoid Hemorrhage: Case Report and Literature Review

Marie Christine Brunet, Stephanie H. Chen, Priyank Khandelwal, Joshua Hare, Robert M. Starke, Eric C. Peterson, Dileep R Yavagal

Research output: Contribution to journalArticle

Abstract

Background: Aneurysmal subarachnoid hemorrhage (SAH) is associated with high mortality (30%–40%) and morbidity with long-term physical, neurologic, and psychological impairments; most patients present with high initial Hunt and Hess grade. In view of the great need for efficacious therapies for high-grade SAH, recent animal studies have demonstrated improved outcomes with administration of mesenchymal stem cells (MSCs) as a potential neuroregenerative strategy. We present the first case of human intravenous administration of MSCs after aneurysmal SAH. Clinical Presentation: An 80-year-old man presented with sudden severe headache with nausea and vomiting. Computed tomography demonstrated SAH with hydrocephalus from a ruptured basilar tip aneurysm. Initial examination of the patient showed Hunt and Hess grade 5 and World Federation of Neurosurgical Societies grade 5. The patient was treated with external ventricular drain placement and coiling of aneurysm. The patient received an infusion of intravenous bone marrow–derived allogeneic MSCs on day 3 postbleed. The patient made a better recovery than anticipated with a modified Rankin Scale score of 3 at 6 months. Conclusions: Several studies using models of ischemic brain injury have found that administration of MSCs may improve functional neurologic recovery and decrease brain lesion volume. Although there have been limited human studies in patients with stroke, the role of stem cell therapy for aneurysmal SAH remains unclear. This is the first case of use of MSCs in a patient for treatment of aneurysmal SAH. In conjunction with the promising results in animal studies, this encouraging preliminary case report supports the need for additional clinical trials.

Original languageEnglish (US)
Pages (from-to)573-575
Number of pages3
JournalWorld neurosurgery
Volume128
DOIs
StatePublished - Aug 1 2019

Fingerprint

Subarachnoid Hemorrhage
Cell- and Tissue-Based Therapy
Stem Cells
Mesenchymal Stromal Cells
Nervous System
Aneurysm
Hydrocephalus
Intravenous Infusions
Intravenous Administration
Brain Injuries
Nausea
Vomiting
Headache
Stroke
Tomography
Clinical Trials
Psychology
Morbidity
Bone and Bones
Mortality

Keywords

  • Aneurysm
  • Stem cells
  • Stroke
  • Subarachnoid hemorrhage

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Intravenous Stem Cell Therapy for High-Grade Aneurysmal Subarachnoid Hemorrhage : Case Report and Literature Review. / Brunet, Marie Christine; Chen, Stephanie H.; Khandelwal, Priyank; Hare, Joshua; Starke, Robert M.; Peterson, Eric C.; Yavagal, Dileep R.

In: World neurosurgery, Vol. 128, 01.08.2019, p. 573-575.

Research output: Contribution to journalArticle

Brunet, Marie Christine ; Chen, Stephanie H. ; Khandelwal, Priyank ; Hare, Joshua ; Starke, Robert M. ; Peterson, Eric C. ; Yavagal, Dileep R. / Intravenous Stem Cell Therapy for High-Grade Aneurysmal Subarachnoid Hemorrhage : Case Report and Literature Review. In: World neurosurgery. 2019 ; Vol. 128. pp. 573-575.
@article{25426276eb34439eb13029622ae30619,
title = "Intravenous Stem Cell Therapy for High-Grade Aneurysmal Subarachnoid Hemorrhage: Case Report and Literature Review",
abstract = "Background: Aneurysmal subarachnoid hemorrhage (SAH) is associated with high mortality (30{\%}–40{\%}) and morbidity with long-term physical, neurologic, and psychological impairments; most patients present with high initial Hunt and Hess grade. In view of the great need for efficacious therapies for high-grade SAH, recent animal studies have demonstrated improved outcomes with administration of mesenchymal stem cells (MSCs) as a potential neuroregenerative strategy. We present the first case of human intravenous administration of MSCs after aneurysmal SAH. Clinical Presentation: An 80-year-old man presented with sudden severe headache with nausea and vomiting. Computed tomography demonstrated SAH with hydrocephalus from a ruptured basilar tip aneurysm. Initial examination of the patient showed Hunt and Hess grade 5 and World Federation of Neurosurgical Societies grade 5. The patient was treated with external ventricular drain placement and coiling of aneurysm. The patient received an infusion of intravenous bone marrow–derived allogeneic MSCs on day 3 postbleed. The patient made a better recovery than anticipated with a modified Rankin Scale score of 3 at 6 months. Conclusions: Several studies using models of ischemic brain injury have found that administration of MSCs may improve functional neurologic recovery and decrease brain lesion volume. Although there have been limited human studies in patients with stroke, the role of stem cell therapy for aneurysmal SAH remains unclear. This is the first case of use of MSCs in a patient for treatment of aneurysmal SAH. In conjunction with the promising results in animal studies, this encouraging preliminary case report supports the need for additional clinical trials.",
keywords = "Aneurysm, Stem cells, Stroke, Subarachnoid hemorrhage",
author = "Brunet, {Marie Christine} and Chen, {Stephanie H.} and Priyank Khandelwal and Joshua Hare and Starke, {Robert M.} and Peterson, {Eric C.} and Yavagal, {Dileep R}",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.wneu.2019.04.055",
language = "English (US)",
volume = "128",
pages = "573--575",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Intravenous Stem Cell Therapy for High-Grade Aneurysmal Subarachnoid Hemorrhage

T2 - Case Report and Literature Review

AU - Brunet, Marie Christine

AU - Chen, Stephanie H.

AU - Khandelwal, Priyank

AU - Hare, Joshua

AU - Starke, Robert M.

AU - Peterson, Eric C.

AU - Yavagal, Dileep R

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Background: Aneurysmal subarachnoid hemorrhage (SAH) is associated with high mortality (30%–40%) and morbidity with long-term physical, neurologic, and psychological impairments; most patients present with high initial Hunt and Hess grade. In view of the great need for efficacious therapies for high-grade SAH, recent animal studies have demonstrated improved outcomes with administration of mesenchymal stem cells (MSCs) as a potential neuroregenerative strategy. We present the first case of human intravenous administration of MSCs after aneurysmal SAH. Clinical Presentation: An 80-year-old man presented with sudden severe headache with nausea and vomiting. Computed tomography demonstrated SAH with hydrocephalus from a ruptured basilar tip aneurysm. Initial examination of the patient showed Hunt and Hess grade 5 and World Federation of Neurosurgical Societies grade 5. The patient was treated with external ventricular drain placement and coiling of aneurysm. The patient received an infusion of intravenous bone marrow–derived allogeneic MSCs on day 3 postbleed. The patient made a better recovery than anticipated with a modified Rankin Scale score of 3 at 6 months. Conclusions: Several studies using models of ischemic brain injury have found that administration of MSCs may improve functional neurologic recovery and decrease brain lesion volume. Although there have been limited human studies in patients with stroke, the role of stem cell therapy for aneurysmal SAH remains unclear. This is the first case of use of MSCs in a patient for treatment of aneurysmal SAH. In conjunction with the promising results in animal studies, this encouraging preliminary case report supports the need for additional clinical trials.

AB - Background: Aneurysmal subarachnoid hemorrhage (SAH) is associated with high mortality (30%–40%) and morbidity with long-term physical, neurologic, and psychological impairments; most patients present with high initial Hunt and Hess grade. In view of the great need for efficacious therapies for high-grade SAH, recent animal studies have demonstrated improved outcomes with administration of mesenchymal stem cells (MSCs) as a potential neuroregenerative strategy. We present the first case of human intravenous administration of MSCs after aneurysmal SAH. Clinical Presentation: An 80-year-old man presented with sudden severe headache with nausea and vomiting. Computed tomography demonstrated SAH with hydrocephalus from a ruptured basilar tip aneurysm. Initial examination of the patient showed Hunt and Hess grade 5 and World Federation of Neurosurgical Societies grade 5. The patient was treated with external ventricular drain placement and coiling of aneurysm. The patient received an infusion of intravenous bone marrow–derived allogeneic MSCs on day 3 postbleed. The patient made a better recovery than anticipated with a modified Rankin Scale score of 3 at 6 months. Conclusions: Several studies using models of ischemic brain injury have found that administration of MSCs may improve functional neurologic recovery and decrease brain lesion volume. Although there have been limited human studies in patients with stroke, the role of stem cell therapy for aneurysmal SAH remains unclear. This is the first case of use of MSCs in a patient for treatment of aneurysmal SAH. In conjunction with the promising results in animal studies, this encouraging preliminary case report supports the need for additional clinical trials.

KW - Aneurysm

KW - Stem cells

KW - Stroke

KW - Subarachnoid hemorrhage

UR - http://www.scopus.com/inward/record.url?scp=85068209853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068209853&partnerID=8YFLogxK

U2 - 10.1016/j.wneu.2019.04.055

DO - 10.1016/j.wneu.2019.04.055

M3 - Article

C2 - 30981798

AN - SCOPUS:85068209853

VL - 128

SP - 573

EP - 575

JO - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

ER -